Vaxcyte, Inc. is a clinical-stage vaccine innovation company developing high-fidelity vaccines against bacterial diseases using its XpressCF cell-free protein synthesis platform. Its pipeline includes VAX-31 (31-valent pneumococcal conjugate vaccine for adults and children), VAX-24 (24-valent PCV for infants), VAX-XL (next-generation broad-spectrum PCV), VAX-A1 (Group A Streptococcus conjugate vaccine), and VAX-GI (Shigella vaccine). VAX-31 has FDA breakthrough therapy designation for prevention of IPD and pneumonia in adults.
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001649094-26-000007 | EDGAR | 111K words |
| 2025-02-25 | 2024-12-31 | 0001649094-25-000028 | EDGAR | 105K words |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021145 | EDGAR | 118K words |
| 2023-02-27 | 2022-12-31 | 0000950170-23-004654 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002281 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001564590-21-016110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001649094-26-000043 | EDGAR | 64K words |
| 2025-11-04 | 2025-09-30 | 0001649094-25-000114 | EDGAR | 65K words |
| 2025-08-06 | 2025-06-30 | 0001649094-25-000098 | EDGAR | 65K words |
| 2025-05-07 | 2025-03-31 | 0001649094-25-000074 | EDGAR | 64K words |
| 2024-11-05 | 2024-09-30 | 0001649094-24-000097 | EDGAR | 71K words |
| 2024-08-06 | 2024-06-30 | 0001649094-24-000052 | EDGAR | 70K words |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021677 | EDGAR | 68K words |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059395 | EDGAR | 75K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039817 | EDGAR | 73K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018835 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022597 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015501 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-03 | 0001649094-26-000045 | EDGAR | 2K words |
| 2026-08-05 | 0001649094-26-000041 | EDGAR | 3K words |
| 2026-07-15 | 0001649094-26-000030 | EDGAR | 1K words |
| 2026-02-24 | 0001193125-26-067546 | EDGAR | 23K words |
| 2026-02-24 | 0001649094-26-000005 | EDGAR | 4K words |
| 2026-02-02 | 0001193125-26-033578 | EDGAR | 22K words |
| 2025-12-19 | 0001649094-25-000116 | EDGAR | 1K words |
| 2025-11-04 | 0001649094-25-000112 | EDGAR | 3K words |
| 2025-09-30 | 0001649094-25-000102 | EDGAR | 1K words |
| 2025-08-06 | 0001649094-25-000096 | EDGAR | 3K words |
108 total filings indexed. 80 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649094 |
| Ticker | PCVX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.vaxcyte.com |
| Listed | 2020-06-12 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PCVX (~200 tokens, structured JSON with cryptographic provenance)